These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study. Heath JA, Steinherz PG, Altman A, Sather H, Jhanwar S, Halpern S, Pieters R, Shah N, Steinherz L, Tannous R, Terry W, Trigg ME, Children's Cancer Group. J Clin Oncol; 2003 Apr 15; 21(8):1612-7. PubMed ID: 12697887 [Abstract] [Full Text] [Related]
24. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma. Lemoli RM, Rosti G, Visani G, Gherlinzoni F, Miggiano MC, Fortuna A, Zinzani P, Tura S. J Clin Oncol; 1996 Nov 15; 14(11):3018-25. PubMed ID: 8918500 [Abstract] [Full Text] [Related]
25. Clinical effect of prophylactic pegfilgrastim in patients with newly diagnosed acute lymphoblastic leukemia who receive intensive chemotherapy. Lee Y, Jang Y, Lee JM, Cho HJ, Moon JH, Sohn SK, Ham JY, Chang SH, Baek DW. Support Care Cancer; 2024 Oct 08; 32(11):715. PubMed ID: 39377915 [Abstract] [Full Text] [Related]
35. [The potential prognostic influence of granulocyte-colony stimulating factor in acute leukemia]. Liu XM, Chen YZ, Huang MJ, Liu X, Guo JR. Zhonghua Nei Ke Za Zhi; 2005 Jul 08; 44(7):518-21. PubMed ID: 16080844 [Abstract] [Full Text] [Related]
36. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Schmitz N, Dreger P, Zander AR, Ehninger G, Wandt H, Fauser AA, Kolb HJ, Zumsprekel A, Martin A, Hecht T. Bone Marrow Transplant; 1995 Feb 08; 15(2):261-6. PubMed ID: 7539668 [Abstract] [Full Text] [Related]
38. Effect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies. Kang KW, Kim DS, Lee SR, Sung HJ, Kim SJ, Choi CW, Kim BS, Park Y. Leuk Res; 2017 Jun 08; 57():1-8. PubMed ID: 28231491 [Abstract] [Full Text] [Related]
39. Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF. Laughlin MJ, Kirkpatrick G, Sabiston N, Peters W, Kurtzberg J. Ann Hematol; 1993 Dec 08; 67(6):267-76. PubMed ID: 7506580 [Abstract] [Full Text] [Related]